Women's Heart Advisor October 2011 Issue

New Warnings Emerge for Estrogen Plus Progesterone

Two studies confirm major cardiovascular risks outweigh minor health benefits for postmenopausal women.

If you take hormone replacement therapy with estrogen plus progesterone (EP) to relieve the symptoms of menopause, you may want to consider switching to an alternative treatment. Thatís because followup studies of two large, important clinical trials confirmed that EP actually increases the risk of coronary heart disease (CHD) for two years after it is taken, and only begins to offer some cardio protection after six years. Additionally, it increases the risk of breast cancer in postmenopausal women, and an increased risk of death from breast cancer and other causes persists after EP is discontinued.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.